申请人:Takeda Chemical Industries, Ltd.
公开号:US05506267A1
公开(公告)日:1996-04-09
A compound of the invention is represented by the formula: ##STR1## wherein R.sup.1 and R.sup.2 are the same or different, an acyl group; R.sup.3, R.sup.4, R.sup.6 and R.sup.7 are the same or different, hydrogen or an alkyl group; R.sup.5 is hydrogen, an alkyl group or a hydroxyl group which may optionally be protected, or R.sup.4 and R.sup.5 are combined to form a chemical bond; X is a carbonyl group or a sulfonyl group; Y is an amino acid sequence consisting of 1 to 7 amino acid residues which may optionally be protected and having optionally an intervening --SO.sub.2 NH--; n is an integer of 0 to 2, or a salt thereof. The compound or salt thereof of the present invention possesses immunoenhancing activity and platelet reduction recovery activity, and can be used as a prophylactic/therapeutic agent for leukocytopenia in cancer chemotherapy or radiotherapy, as an immunoenhancing agent in bone marrow transplantation therapy and the treatment of osteomyelodysplasia and aplastic anemia, and as a prophylactic/therapeutic agent for thrombocytopenia.
该发明的化合物由以下结构式表示:##STR1##
其中R^1和R^2相同或不同,为酰基;R^3、R^4、R^6和R^7相同或不同,为氢或烷基;R^5为氢、烷基或羟基,可选择性地进行保护,或R^4和R^5结合形成化学键;X为羰基或磺酰基;Y为由1至7个氨基酸残基组成的氨基酸序列,可选择性地进行保护,并可具有可选的--SO_2NH--插入基团;n为0至2的整数,或其盐。本发明的化合物或其盐具有免疫增强活性和血小板减少恢复活性,可用作癌症化疗或放疗中白细胞减少的预防/治疗药物,用作骨髓移植治疗和骨髓增生异常和再生障碍性贫血的免疫增强剂,以及用作血小板减少的预防/治疗药物。